Why this matters for dosing The extended half-life means: Once-weekly injections are sufficient the drug does not need to be taken daily Steady-state levels build up over several weeks this is another reason why gradual titration works well
24 They are prescribed for type 2 diabetes mellitus (T2DM) and obesity, for which they currently have approval from the United States (US) Food and Drug Administration (FDA)
The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving
Key takeaways Nausea is the most common side effect of Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo, and the most common reason patients in trials and in clinic consider stopping
For patients using continuous glucose monitoring (CGM) or regular fingerstick testing, improvements in time in range (glucose levels between 3.910.0 mmol/L) may be observed within days to weeks
Transition to Branded Medications : Begin prescribing Wegovy or Ozempic, ensuring prescribers are trained on eligibility criteria (e.g., BMI thresholds)
